Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ILC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILC Seeks \u00a34m to Help Advance COVID-19 Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"ILC Therapeutics","sponsor":"ILC Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ILC Therapeutics Announces Research Partnership with University of St Andrews to Fight Against COVID-19","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"ILC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ILC Therapeutics Announces \u2018Significant\u2019 COVID-19 Drug Breakthrough","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"ILC Therapeutics","sponsor":"Eos Angel Investment Syndicate","pharmaFlowCategory":"D","amount":"$4.8 million","upfrontCash":"Undisclosed","newsHeadline":"Scottish Biotech ILC Therapeutics Sets Sights on Series A and IPO After Recent Investment Round","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by ILC Therapeutics

    Menu

    ILC Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ILC Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Scottish Biotech ILC Therapeutics Sets Sights on Series A and IPO After Recent Investment Round

              Details:

              The financing will be used in the development for ILC’s lead hybrid interferon drug, Alfacyte (human alpha interferon), an anti-viral medicine for the treatment of upper respiratory tract viral infections, including SARS-CoV-2 which causes Covid-19.

              Lead Product(s): Human Alpha Interferon

              Therapeutic Area: Infections and Infectious Diseases Product Name: Alfacyte

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Eos Angel Investment Syndicate

              Deal Size: $4.8 million Upfront Cash: Undisclosed

              Deal Type: Financing April 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ILC Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ILC Therapeutics Announces ‘Significant’ COVID-19 Drug Breakthrough

              Details:

              ILC Therapeutics' unique synthetic Interferon called Alfacyte™ is fifteen to twenty times more effective at preventing the spread of SARS-CoV-2 in cell culture than other commercially-available Interferons such as Interferon alpha 2 and Interferon beta 1a.

              Lead Product(s): IFN Alpha-14

              Therapeutic Area: Infections and Infectious Diseases Product Name: Alfacyte

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 07, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ILC Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ILC Therapeutics Announces Research Partnership with University of St Andrews to Fight Against COVID-19

              Details:

              The collaborative work between ILC Therapeutics and Dr. Catherine Adamson from the School of Biology at the University of St Andrews, will focus on the role that Alfacyte can play in preventing COVID-19-indusced acute respiratory distress syndrome (ARDS).

              Lead Product(s): Alfacyte

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Alfacyte

              Highest Development Status: Undisclosed Product Type: Large molecule

              Recipient: University of St Andrews

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement June 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ILC Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ILC Seeks £4m to Help Advance COVID-19 Trials

              Details:

              The company has patented a new Interferon-Alpha subtype called Interferon Alpha 14 which can be given to patients through injection or inhalation.

              Lead Product(s): Interferon Alpha 14

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 30, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY